- RFP Year2020
- Awarded Amount$2,622,542
- DiseaseNTD (Schistosomiasis)
- Development StageRegistration
- Collaboration PartnersAstellas Pharma Inc., Kenya Medical Research Institute (KEMRI-CGHR), Klinikum rechts der Isar der Technischen Universität München, Department of Neurology (MRI), Merck KGaA, SCI Foundation, Swiss Tropical and Public Health Institute, Université Félix Houphouët Boigny (UFHB), Lygature
- Past Project
Introduction and Background of the Project
Schistosomiasis, also known as bilharzia and endemic in 78 developing countries, is a chronic inflammatory neglected tropical disease caused by parasitic worms. The disease affects more than 206 million people, including 100 million children, globally. It is one of the most prevalent tropical diseases in the world after malaria, and represents an important health burden in developing countries, especially in Africa where more than 90% of the infections occur.
The current gold standard recommended treatment for schistosomiasis, praziquantel (PZQ), is available in oral tablets for adults and children, but the effective dose for children < 4 years is currently not known as pharmacokinetics or dose-finding clinical studies have never been systematically conducted in this age group until recently. In addition, a pediatric formulation of praziquantel that would be appropriate for preschool age children, infants and toddlers, and would permit accurate dosing and enhanced compliance in these patients is non-existent and highly needed. The development of a new pediatric formulation of praziquantel is to be seen in the current context of the WHO’s 2020 Roadmap and with respect to the upcoming NTD Roadmap 2021-2030 under which the global community agreed on control and elimination of schistosomiasis.
The Pediatric Praziquantel Consortium is an international not-for-profit partnership that aims to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children. Its mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in this age group. The pediatric formulation, currently under investigation in a Phase III clinical trial, has been designed to be smaller, exhibit an improved palatability and be orally dispersible compared to the current commercial formulation. The next steps will focus on establishing optimal Levo-Praziquantel access and delivery strategies for different endemic settings in Africa.
The Consortium was established in July 2012 by Merck KGaA, Darmstadt, Germany (Merck KGaA), Astellas Pharma Inc. (Astellas), Swiss Tropical and Public Health Institute (Swiss TPH) and Lygature (formerly TI Pharma). At the beginning of 2014, Farmanguinhos and Simcyp, a Certara company, joined the Consortium as full partners. The Schistosomiasis Control Initiative (SCI) joined in 2016. At the end of 2017 Simcyp completed all its tasks around PK modeling and left the Consortium. In Jan 2018 Université Félix Houphouët Boigny (UFHB) and Kenya Medical Research Institute (KEMRI) joined the Consortium as new partners. In 2020, the Consortium will be strengthened with the Technical University of Munich (TUM). Since the start, all partners have been efficiently working together to progress the project and achieve the pre-clinical, clinical phase I-III and registration objectives.
All partners are bound by a Consortium agreement, which arranges their roles and responsibilities and includes a formal governance structure with a Consortium Board as the highest decision-making body, and Lygature as independent Coordinator. An external expert panel is called by the Consortium prior to each clinical development stage to provide an independent evaluation of the project. The partners have formed a core project team, led by Merck KGaA, comprising one representative of each partner and/or expertise area that meets every month. The core project team is supported by various subteams focusing on specific technical and operational aspects to implement the consortium’s program.
How can your partnership (project) address global health challenges?
In order to tackle the important public health problem of schistosomiasis, the non-profit Pediatric Praziquantel Consortium has been formed in July 2012 to develop a pediatric formulation of praziquantel. The project will contribute to the overall goal of control and elimination of schistosomiasis by developing a product urgently required for the treatment of preschool-age children, infants and toddlers, a population that is currently being considered by WHO to be included in treatment campaigns. The development and registration of a new pediatric formulation of praziquantel is regarded by the Consortium as a cornerstone to fulfill the WHO commitment to address the health burden that schistosomiasis represents and the importance of controlling disease-related morbidities. To achieve this commitment, several measures need to be integrated among which making chemotherapy treatment available to all age groups is an important part of.
What sort of innovation are you bringing in your project?
The Pediatric Praziquantel Consortium has developed and optimized pediatric orodispersible tablet (ODT) formulations of the enantiopure R-(-)-PZQ and racemate PZQ (back up) that will permit preschool-age children to be targeted for treatment thus closing the major treatment gap mentioned above. The target was to have a new ODT formulation that preferably contains the enantiopure R-(-)-praziquantel (L-PZQ ODT), since the schistosomicidal activity arises only from R-(-)-praziquantel, which has also been reported to be less bitter than racemate PZQ. Based on the outcome of the Phase I program and discussions with key stakeholders, including WHO PQP and WHO NTD, the Consortium included both formulations in the Phase II trial in children (age 3 months to 6 years) infected with S. mansoni in Cote d’Ivoire. Data from the Phase II pediatric trial (2-6 years) led to the selection of the L-PZQ ODT formulation at a dose of 50 mg/kg to be pursued for the phase III trial, the current stage of the development program.
Role and Responsibility of Each Partner
Merck KGaA (Darmstadt, Germany) leads the program and brings expertise and support related to praziquantel, including resources from different areas (drug product manufacturing, pre-clinical, clinical, regulatory) needed for clinical development & registration and to efficiently execute the project. Astellas contributes by providing in-kind expert advice to support communication activities of the Consortium in order to secure procurement and funding for large-scale distribution of Levo-Praziquantel across endemic countries.. Swiss TPH brings extensive experience in helminths biological and pharmacological research, epidemiology and clinical research in endemic regions. The governance is facilitated by Lygature, a Dutch non-profit organization and independent party with an extensive portfolio of international public-private partnerships in drug research and development, including in the area of neglected diseases. KEMRI and UFHB will provide expertise on local disease epidemiology and clinical care, considered key elements of the access strategy. SCI provides the necessary expertise to define and execute the access strategy and plan as well as to initiate and implement NTD control and elimination programs in Sub-Saharan Africa. Finally, TUM, represented by the Center for Global Health, complements the Consortium with its multidisciplinary and multicultural expertise in the field of neglected tropical diseases with a special focus on social science in global health.
Others (including references if necessary)
For more detailed information on the Pediatric Praziquantel Consortium, the project team and the development program, please feel free to visit the Consortium website:
To receive regular updates on the progress and activities of the program, feel free to sign-up for the bi-annual Consortium Newsletter: